指南与共识新发突发、热带与寄生虫病医院感染防控

美国感染病学会COVID-19诊断指南解读

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19.
指南 / 共识 · Clin Infect Dis · 2020-06-16

美国感染病学会(IDSA)组织多学科专家组,采用GRADE方法评估证据,就SARS-CoV-2核酸扩增检测的临床应用达成15条诊断推荐。指南推荐对所有疑似COVID-19的有症状者及有已知或疑似接触的无症状者进行核酸检测,并指出当前文献证据质量低至极低。

要点

  • 推荐对所有疑似COVID-19的有症状个体进行SARS-CoV-2核酸检测。
  • 推荐对有已知或疑似COVID-19接触史的无症状者进行核酸检测。
  • 无症状无已知暴露者,仅在结果影响隔离/PPE/手术/免疫抑制治疗决策时建议检测。

核心结论

  • IDSA专家组基于现有诊断证据推荐对所有疑似COVID-19的有症状个体进行SARS-CoV-2核酸检测。
  • 推荐对有已知或疑似COVID-19病例接触史的无症状个体进行核酸检测。
  • 对于无已知暴露的无症状个体,当结果将影响隔离/检疫/个人防护装备使用决策、手术资格或免疫抑制治疗管理时,建议进行检测。

研究设计与样本

  • IDSA召集了由感染病临床医生、临床微生物学家和系统文献综述专家组成的多学科专家组。
  • 采用GRADE方法评估证据确定性并制定检测推荐。
  • 专家组就15条诊断推荐达成共识。

主要发现

  • 专家组就15条诊断推荐达成共识。
  • 当前文献中关于可用检测临床性能的证据质量被评定为低至极低。

关键数值与推荐

  • 推荐对所有疑似COVID-19的有症状个体进行核酸检测。
  • 推荐对有已知或疑似COVID-19病例接触史的无症状个体进行核酸检测。
  • 对于无已知暴露的无症状个体,当结果将影响隔离/检疫/PPE使用决策、手术资格或免疫抑制治疗管理时,建议进行检测。

临床怎么用

  • 临床医生应优先对有症状疑似COVID-19患者进行SARS-CoV-2核酸检测。
  • 对有明确接触史的无症状者应进行检测以指导隔离和暴露后管理。
  • 无暴露无症状者的检测应基于结果对临床决策(如手术、免疫抑制治疗)的实际影响。
  • 检测优先级最终取决于机构资源和不同患者群体的需求。

局限性

  • 当前文献证据质量被评定为低至极低。
  • 检测优先级需依赖机构特定资源和患者群体需求,可能影响指南的普遍适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate molecular diagnostic tests are necessary for confirming a diagnosis of coronavirus disease 2019 (COVID-19). Direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare institution and public health level decision-making. The numbers of available SARS-CoV-2 nucleic acid detection tests are rapidly increasing, as is the COVID-19 diagnostic literature. Thus, the Infectious Diseases Society of America (IDSA) recognized a significant need for frequently updated systematic reviews of the literature to inform evidence-based best practice guidance. OBJECTIVE: The IDSA's goal was to develop an evidence-based diagnostic guideline to assists clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of SARS-CoV-2 nucleic acid amplification tests. In addition, we provide a conceptual framework for understanding molecular diagnostic test performance, discuss the nuance of test result interpretation in a variety of practice settings, and highlight important unmet research needs in the COVID-19 diagnostic testing space. METHODS: IDSA convened a multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review to identify and prioritize clinical questions and outcomes related to the use of SARS-CoV-2 molecular diagnostics. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. RESULTS: The panel agreed on 15 diagnostic recommendations. CONCLUSIONS: Universal access to accurate SARS-CoV-2 nucleic acid testing is critical for patient care, hospital infection prevention and the public response to the COVID-19 pandemic. Information on the clinical performance of available tests is rapidly emerging, but the quality of evidence of the current literature is considered low to very low. Recognizing these limitations, the IDSA panel weighed available diagnostic evidence and recommends nucleic acid testing for all symptomatic individuals suspected of having COVID-19. In addition, testing is recommended for asymptomatic individuals with known or suspected contact with a COVID-19 case. Testing asymptomatic individuals without known exposure is suggested when the results will impact isolation/quarantine/personal protective equipment (PPE) usage decisions, dictate eligibility for surgery, or inform administration of immunosuppressive therapy. Ultimately, prioritization of testing will depend on institutional-specific resources and the needs of different patient populations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hanson KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. Clin Infect Dis. 2020. PMID: 32556191. doi:10.1093/cid/ciaa760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。